NATIONAL BUREAU OF ECONOMIC RESEARCH
University Of Paris 1 Pantheon Sorbonne
106 - 112 Boulevard De L'Hopital
Paris CEDEX 13
NBER Working Papers and Publications
|May 2008||Pharmaceutical innovation and the longevity of Australians: a first look|
with Frank R. Lichtenberg: w14009
We examine the impact of pharmaceutical innovation on the longevity of Australians during the period 1995-2003. Due to the government's Pharmaceutical Benefits Scheme, Australia has much better data on drug utilization than most other countries. We find that mean age at death increased more for diseases with larger increases in mean drug vintage. The estimates indicate that increasing the mean vintage of drugs by 5 years would increase mean age at death by almost 11 months. The estimates also indicate that using newer drugs reduced the number of years of potential life lost before the ages of 65 and 70 (but not before age 75). During the period 1995-2003, mean age at death increased by about 2.0 years, from 74.4 to 76.4. The estimates imply that, in the absence of any increase in drug vint...